地诺单抗国内售价多少？

It is the first approved monoclonal antibody specifically targeting RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Osteoclasts are responsible for bone resorption, and osteoclast precursors must have low levels of macrophage colony-stimulating factor and RANKL during their differentiation into mature osteoclasts. This product has a high affinity with RANKL, preventing RANK ligand from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis.

On May 27, 2019, Amgen China announced today that Engavir® (English trade name: In 2018, denosumab was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

The therapeutic effect of denosumab is so remarkable, so what is its price in China?

Although the country conditionally approved denosumab for marketing in May 2019, due to the conditional approval and the fact that it was only on the market for five months, the domestic selling price of this drug cannot be collected. What is certain is that as an imported original drug, a new drug, and a special drug, the price of denosumab in China must be very high. According to Medical Companion Travel, denosumab currently on the market in the United States is 60mg/1ml tube/box, priced at US$1,169.98. The price is relatively high, and most patients cannot afford the high medical expenses. Fortunately, the product produced by Amgen of the United States has been launched in Turkey. The specification is 125mg/1ml tube/box, and the price is equivalent to about RMB 3,000. It can be said to be high quality and low price. Therefore, more and more patients choose denosumab marketed in Turkey by Amgen of the United States.